Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shreyas Gangadhara

Neurology Jackson, MS Medical Doctor

NPI 1992092548 CMS profile 1388558

2500 N State St, Jackson, MS 39216

Open in the dashboard

General payments

$20,357

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shreyas Gangadhara of Jackson, MS is reported in the CMS Open Payments database as having received $20,357 across 168 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82 4
2024 General $38 1
2023 General $378 17
2022 General $13,584 63
2021 General $5,881 59
2020 General $222 14
2019 General $173 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shreyas Gangadhara
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Shreyas Gangadhara were reported at $82. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Shreyas Gangadhara Neurology median Middle half National median
2019 $173 $474 $118–$2,177 $163
2020 $222 $367 $82–$2,309 $114
2021 $5,881 $438 $104–$2,547 $132
2022 $13,584 $442 $103–$2,388 $149
2023 $378 $464 $119–$2,312 $160
2024 $38 $468 $119–$2,323 $164
2025 $82 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $17,352 24 payments
  2. UCB, Inc. $336 13 payments
  3. ACADIA Pharmaceuticals Inc $246 14 payments
  4. CSL Behring $222 4 payments
  5. Novartis Pharmaceuticals Corporation $214 10 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $190 11 payments
  7. LivaNova USA, Inc. $189 2 payments
  8. Biohaven Pharmaceuticals, Inc. $178 11 payments
  9. Genzyme Corporation $150 9 payments
  10. SK Life Science, Inc. $149 6 payments
  11. Other $1,131 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,733 11 payments
  2. Food and Beverage $3,523 153 payments
  3. Travel and Lodging $1,101 4 payments
Products named General payments · program years 2019–2025
  1. BRILINTA $17,216 21 payments
  2. NURTEC ODT $368 22 payments
  3. Briviact $336 13 payments
  4. Kcentra $199 3 payments
  5. NUPLAZID $161 9 payments
  6. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $151 1 payment
  7. AUBAGIO $150 9 payments
  8. KESIMPTA $120 6 payments
  9. ANDEXXA $113 1 payment
  10. AIMOVIG $103 5 payments
  11. Other $1,546 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

399

Median for Neurology: 833

Drug cost

$49,446

Median for Neurology: $202,670

Branded share of claims

17.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 17 $22,982
Vimpat Lacosamide Brand 12 $13,812
Repatha Sureclick Evolocumab Brand 13 $7,181
Lacosamide Generic 30 $1,569
Levetiracetam Generic 42 $1,262
Gabapentin Generic 31 $686
Atorvastatin Calcium Generic 86 $613
Pregabalin Generic 27 $330
Donepezil Hcl Generic 40 $219
Ezetimibe Generic 15 $209

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$33,970

Medicare's payments for the services billed

Medicare patients

253

Average age 73

Services billed

436

132 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 46%
Ischemic heart disease 39%
Depression 29%
Atrial fibrillation 27%
Chronic kidney disease 26%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record